302 related articles for article (PubMed ID: 26779767)
1. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
2. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
7. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
Lewis AR; Costello BA; Quevedo F; Pagliaro LC; Sanhueza C; Weinshilboum RM; Kalari KR; Wang L; Kohli M; Tan W; Giridhar KV
Prostate; 2023 May; 83(7):649-655. PubMed ID: 36924119
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
9. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
11. Plasma progastrin-releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis-targeted agents in patients with metastatic castration-resistant prostate cancer.
Yashi M; Nishihara D; Yokoyama M; Fuchizawa H; Okazaki A; Takei K; Suzuki I; Sakamoto K; Kijima T; Kobayashi M; Kamai T
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1762. PubMed ID: 36470854
[TBL] [Abstract][Full Text] [Related]
12. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
[TBL] [Abstract][Full Text] [Related]
14. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC
Oncology; 2016; 90(2):69-78. PubMed ID: 26771576
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
Fan L; Yang Y; Chi C; Ma X; Wang R; Gong Y; Zheng H; Pan J; Zhu Y; Dong B; Xue W
Prostate; 2019 May; 79(6):567-573. PubMed ID: 30614033
[TBL] [Abstract][Full Text] [Related]
16. Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
Kim KB; Jo JK; Ahn S; Lee S; Jeong SJ; Hong SK; Byun SS; Lee SE
Korean J Urol; 2015 Aug; 56(8):580-6. PubMed ID: 26279827
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
[TBL] [Abstract][Full Text] [Related]
18. Gastrin-releasing peptide: predictor of castration-resistant prostate cancer?
Heinrich E; Probst K; Michel MS; Trojan L
Prostate; 2011 May; 71(6):642-8. PubMed ID: 20945407
[TBL] [Abstract][Full Text] [Related]
19. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
Han CS; Patel R; Kim IY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
